Isolated bispecific antibodies that specifically bind CD47 and PD-L1

The invention relates to the field of biotechnology and medicine, in particular to a bispecific antibody specifically binding to CD47 and PD-L1. The invention further relates to nucleic acids encoding said bispecific antibodies, expression vectors, host cells for producing said bispecific antibodies and methods for producing said cells, pharmaceutical compositions comprising the bispecific antibodies according to the invention, and methods for producing said cells. The present invention relates to bispecific antibodies and other therapeutically active compounds, pharmaceutical compositions comprising the bispecific antibodies according to the invention and other therapeutically active compounds, methods for treating diseases or disorders mediated by CD47 and PD-L1, the use of bispecific antibodies or pharmaceutical compositions thereof for treating diseases or disorders mediated by CD47 and PD-L1, and methods for treating diseases or disorders mediated by CD47 and PD-L1. And the use of the bispecific antibodi